Companies Health care
Novartis
CHF 133.78+CHF 1.48 (+1.12%) on the day
Health care, Drug Manufacturers - General. Revenue of $56.7bn in the year to Dec 2025, up 9.6%, with an operating margin of 31.1%.
Against its peers
Novartis (filled) against the other 20 health care companies among the 200 largest in the STOXX Europe 600. Tap or hover a dot to read it.
Yahoo Finance, 30 Oct 2026. P/E on the last four quarters' diluted EPS; revenue growth and operating margin for each company's last fiscal year; debt to equity at the last balance sheet; dividend yield on the last 12 months' dividends.
Valuation
A ten-year discounted cash flow model on the last reported free cash flow. Every assumption is on the page: move it and the value follows.
Base: free cash flow of $15.2bn in the year to Dec 2025, net debt of $39.3bn, 1.89bn shares. Converted to Swiss francs at today’s rate, the currency the shares trade in. Growth fades in a straight line from year 6 to year 10. An Andra Markets model, not a recommendation.
Valuation over time
The price to earnings ratio at each month end, on the last fiscal year’s diluted earnings per share known at the time, against its average over the period.
P/EAverage
Month-end closes and annual reports, via Yahoo Finance.
Where revenue goes
Of every $100 of revenue in the year to Dec 2025, Novartis kept $25 as net income.
Annual report for the year to Dec 2025, via Yahoo Finance. Items under 0.5% of revenue are folded into the next line.
Revenue and profit, 4 years
Revenue and net income each fiscal year, in billions of dollars. Tap or hover a year to read it.
RevenueNet income
Annual reports, via Yahoo Finance.
Last 5 quarters
Revenue in billions of dollars and diluted earnings per share, quarter by quarter.
Revenue
Earnings per share
Quarterly reports, via Yahoo Finance. Quarters are named by the month they end.
Cash flow and investment
Cash from operations, what went into capital spending, and the free cash flow left, in billions of dollars.
Cash from operationsCapital spendingFree cash flow
Annual reports, via Yahoo Finance.
Balance sheet
Cash and short-term investments, debt and shareholders’ equity at each fiscal year end, in billions of dollars.
Cash and investmentsDebtEquity
Annual reports, via Yahoo Finance. Debt excludes leases.
Returns to shareholders
Dividends paid and shares bought back each fiscal year, against net income, in billions of dollars.
DividendsBuybacksNet income
Annual reports, via Yahoo Finance.
Share price returns
Price change over each period to the close of 30 Oct 2026, without dividends.
| Series | 1 month | 3 months | Year to date | 1 year |
|---|---|---|---|---|
| Novartis | +13.3% | +7.4% | +22.1% | +35.3% |
| Health care average (21) | +16.1% | +14.9% | +12.5% | +19.9% |
| STOXX Europe 600 | +3.2% | −1.5% | +9.1% | +12.5% |
Yahoo Finance daily closes, in Swiss francs. The sector average is the simple average of its companies among the 200 largest in the STOXX Europe 600.
Against the market
Novartis and the STOXX Europe 600 over the past year, both rebased to 100, each in its own currency.
NovartisSTOXX Europe 600
Yahoo Finance, daily closes to 30 Oct 2026.
Risk
How much the shares move, and how far they have fallen from their high over the past year.
- Volatility, 1 year23%Annualised daily moves; the STOXX Europe 600 moved 12%
- Beta to the STOXX Europe 6000.491.0 moves with the market
- Deepest fall, 1 year−15.0%2 Sep 2026 to 9 Sep 2026
- Below its highAt its highAgainst the year’s highest close
Yahoo Finance daily closes. Beta from daily returns against the STOXX Europe 600.
Investment memo
Coming with the Andra Markets subscription: a full memo on Novartis, written for professionals.
- The thesis and what would change it
- Segment by segment, with the model's full workings
- Three scenarios with their assumptions
- What to watch at the next results
Ahead
No results date in the calendar yet. It appears here once the company or Yahoo Finance posts one.
For information only. Not investment advice.